
Eric Morrow
· Mencoff Family Professor of Biology, Professor of Brain Science, Professor of Neuroscience, Professor of Psychiatry and Human BehaviorBrown University · Genetics
Active 1930–2026
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Eric M. Morrow is the Mencoff Family Professor of Biology, as well as a Professor of Brain Science, Neuroscience, Psychiatry and Human Behavior at Brown University. He received his PhD in genetics and neurodevelopment from Harvard University, his MD from the Health Science Training Program at MIT and Harvard Medical School, and completed further clinical and scientific training in neurology and psychiatry at Harvard Medical School. His research focuses on the genetic and molecular mechanisms underlying disorders of cognitive development, such as autism and intellectual disability. The laboratory investigates mechanisms in neuronal organelles, including endosomes, lysosomes, and mitochondria, as well as neurometabolism, with a particular emphasis on novel human neurogenetic syndromes like Christianson Syndrome and GPT2 Deficiency. These studies aim to understand mechanisms of neuronal vulnerability and neurodegeneration, and to develop molecular therapies for neurogenetic disorders. His work has been funded by NIMH, NINDS, and NIA. Dr. Morrow's research bridges campus and medical school efforts at Brown, and he is actively involved in mentoring students and junior faculty, with a focus on translating genetic and molecular insights into improved diagnosis and treatment interventions for neurodevelopmental disorders.
Research topics
- Genetics
- Biology
- Psychology
- Medicine
- Neuroscience
- Demography
- Environmental health
- Evolutionary biology
- Pathology
- Developmental psychology
Selected publications
Cell · 2020 · 2401 citations
We present the largest exome sequencing study of autism spectrum disorder (ASD) to date (n = 35,584 total samples, 11,986 with ASD). Using an enhanced analytical framework to integrate de novo and case-control rare variation, we identify 102 risk genes at a false discovery rate of 0.1 or less. Of these genes, 49 show higher frequencies of disruptive de novo variants in individuals ascertained to have severe neurodevelopmental delay, whereas 53 show higher frequencies in individuals ascertained t…
Autism Research · 2020 · 52 citations
Senior authorCorrespondingThe objective of this study was to establish a large, densely sampled, U.S. population-based cohort of people with autism spectrum disorder (ASD). The Rhode Island Consortium for Autism Research and Treatment (RI-CART) represents a unique public-private-academic collaboration involving all major points of service for families in Rhode Island affected by ASD. Diagnosis was based on direct behavioral observation via the Autism Diagnostic Observation Schedule, Second Edition. For the first 1,000 pa…
Science Translational Medicine · 2021 · 31 citations
Senior authorCorrespondingexchanger 6 (NHE6). To hasten treatment development, we established induced pluripotent stem cell (iPSC) lines from patients with CS representing a mutational spectrum, as well as biologically related and isogenic control lines. We demonstrated that pathogenic mutations lead to loss of protein function by a variety of mechanisms: The majority of mutations caused loss of mRNA due to nonsense-mediated mRNA decay; however, a recurrent, missense mutation (the G383D mutation) had both loss-of-functio…
A deep learning model for prediction of autism status using whole-exome sequencing data
PLoS Computational Biology · 2024-11-08 · 8 citations
articleOpen accessCorrespondingAutism is a developmental disability. Research demonstrated that children with autism benefit from early diagnosis and early intervention. Genetic factors are considered major contributors to the development of autism. Machine learning (ML), including deep learning (DL), has been evaluated in phenotype prediction, but this method has been limited in its application to autism. We developed a DL model, the Separate Translated Autism Research Neural Network (STAR-NN) model to predict autism status.…
Disease Models & Mechanisms · 2022-11-14 · 8 citations
articleOpen accessSenior author17q12 deletion (17q12Del) syndrome is a copy number variant (CNV) disorder associated with neurodevelopmental disorders and renal cysts and diabetes syndrome (RCAD). Using CRISPR/Cas9 genome editing, we generated a mouse model of 17q12Del syndrome on both inbred (C57BL/6N) and outbred (CD-1) genetic backgrounds. On C57BL/6N, the 17q12Del mice had severe head development defects, potentially mediated by haploinsufficiency of Lhx1, a gene within the interval that controls head development. Phenoty…
Recent grants
Mechanisms of circuit failure and treatments in patient-derived neurons in autism
NIH · $2.8M · 2014–2021
Mechanisms of Disease and Treatment in Novel Metabolic Developmental Brain Disorders
NIH · $3.2M · 2021–2026
NIH · $920k · 2012
Frequent coauthors
- 197 shared
M Schmidt
Brown University
- 160 shared
Matthew F. Pescosolido
Brandeis University
- 154 shared
Christopher A. Walsh
Mount Sinai Hospital
- 113 shared
Li Ma
Brown University
- 107 shared
Brian C. Kavanaugh
Brown University
- 102 shared
Ece D. Gamsiz Uzun
John Brown University
- 94 shared
Qing Ouyang
Brown University
- 88 shared
Jennifer N. Partlow
Howard Hughes Medical Institute
Labs
Education
Ph.D., genetics and neurodevelopment
Harvard University
M.D., Health Science Training (HST) Program
Massachusetts Institute of Technology and Harvard Medical School
Awards & honors
- 2011-2012 Psychiatry Research Mentor Award from the Departme…
Similar researchers at Brown University
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Eric Morrow
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup
